University of California, San Francisco | About UCSF | Search UCSF | UCSF Medical Center
You need to answer all questions correctly to earn continuing medical education credit.
Use of a ritonavir-boosted protease inhibitor
Inclusion of at least 2 active antiretroviral drugs (ARVs)
Use of an integrase inhibitor (eg, raltegravir)
a. It may enhance NNRTI efficacy, in vitro.
b. It is associated with high-level NRTI resistance.
c. It is associated with high-level integrase inhibitor resistance.
d. Choices a and b
TAM 1 pathway (41, 210, 215)
TAM 2 pathway (67, 70, 219)
a. It should include a ritonavir-boosted protease inhibitor.
b. It should include 1 or more NRTIs.
c. It should be based on genotype and phenotype test results.
d. It should be based on tropism testing, if treatment with a CCR5 antagonist is being considered.
e. Choices c and d
About | Site Map | Feedback | Subscribe | Donate | Disclaimer
HIV InSite is a project of the UCSF Center for HIV Information. Copyright 2017, Regents of the University of California.